We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.49 | -1.65% | 29.26 | 29.25 | 29.52 | 29.73 | 29.20 | 29.71 | 6,646,430 | 22:20:00 |
By Kathryn Hardison
International stocks trading in New York closed mostly lower on Monday.
The S&P/BNY Mellon index of American depositary receipts fell 0.2% to 135.22. The European index decreased 0.2% to 131.43, the Asian index fell 0.2% to 152.90, the Latin American index rose 0.5% to 188.64 and the emerging markets index decreased 0.1% to 260.85.
Infineon Technologies AG and Roche Holding AG were among the companies with ADRs that traded actively.
ADRs of Infineon Technologies rose 5% after the chipmaker said Monday that it had signed a nonbinding agreement with car maker Stellantis NV on the supply of semiconductors for electric vehicles. This marks the first step toward a potential multi-year supply of silicon-carbide chips, Infineon said, which are widely used in the industrial and automotive industries.
ADRs of Roche Holding fell 4.6% after the company said that phase three graduate studies of gantenerumab, for treatment of early Alzheimer's disease, failed to meet its primary endpoints.
ADRs of AstraZeneca PLC rose 1.8% after the company said Enhertu has been recommended for approval in the European Union for patients with gastric cancer.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
November 14, 2022 18:09 ET (23:09 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions